NCT00193115View on ClinicalTrials.gov

Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

January 31, 2009

Conditions

Breast Cancer

Interventions

DRUG

Docetaxel

DRUG

Doxorubicin

DRUG

Cyclophosphamide

Sponsors

Collaborators (1)

Aventis Pharmaceuticals

All Listed Sponsors

collaborator

Aventis Pharmaceuticals

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER